Although the biopharmaceutical industry has undergone waves of change and disruptive mergers and acquisitions (M&As) over the past two decades, Mads Krogsgaard Thomsen, chief science officer at Novo Nordisk, has enjoyed relative tranquillity during this time. This year, he celebrates his twentieth anniversary overseeing research and development (R&D). During his long tenure, the veterinary scientist turned pharmacologist has helped Novo Nordisk become one of the top diabetes drug companies by spearheading the optimization of insulin analogues and by championing GLP1 analogues. He talks with Asher Mullard about some of the mistakes he's made and the lessons he's learned from his time at the top.
Enjoying our latest content?
Log in or create an account to continue
- Access the most recent journalism from Nature's award-winning team
- Explore the latest features & opinion covering groundbreaking research
or
Rights and permissions
About this article
Cite this article
Mads Krogsgaard Thomsen. Nat Rev Drug Discov 13, 96–97 (2014). https://doi.org/10.1038/nrd4238
Published:
Issue date:
DOI: https://doi.org/10.1038/nrd4238
